This COVID-19 roundup includes coverage on the latest estimated number of adults with long COVID, WHO’s updated terminology for pathogens that transmit through the air, how COVID-19 vaccination reduces the...
Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...
Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...
Individuals with acute hepatic porphyria often experience acute attacks and chronic symptoms which greatly diminish their quality of life. Researchers examined the efficacy of givosiran in reducing these...
Researchers set out to determine whether microglial activation, which can trigger neuroinflammation, is associated with neuropsychiatric symptoms that often accompany Alzheimer-associated dementias,...
The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...